Page last updated: 2024-11-04

4-nitrobenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitrobenzaldehyde: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-nitrobenzaldehyde : A C-nitro compound that is benzaldehyde substituted at the para-position with a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID541
CHEMBL ID164236
CHEBI ID66926
SCHEMBL ID1157
MeSH IDM0095072

Synonyms (71)

Synonym
wln: wnr dvh
p-formylnitrobenzene
nsc6103
benzaldehyde, p-nitro-
benzaldehyde, 4-nitro-
nsc-6103
AB-131/40217801
nsc 6103
einecs 209-084-5
ai3-52475
ccris 1675
para-nitrobenzaldehyde
4-nitro benzaldehyde
benzaldehyde,4-nitro mfc7 h5 n1 o3
inchi=1/c7h5no3/c9-5-6-1-3-7(4-2-6)8(10)11/h1-5
p-nitrobenzaldehyde
555-16-8
4nbz
4-nitrobenzaldehyde
4-nitrobenzaldehyde, 98%
STK199266
AKOS000118887
CHEMBL164236
4-nitro-benzaldehyde
chebi:66926 ,
N0559
A15647
dtxsid5022061 ,
dtxcid402061
NCGC00260476-01
tox21_202930
cas-555-16-8
BBL011957
4-formylnitrobenzene
FT-0672749
xxh ,
nx859p8mb0 ,
unii-nx859p8mb0
BP-11799
FT-0619200
SCHEMBL1157
(4 nitrophenyl)methanone
p-nitrobenzenealdehyde
4-nitrobenz aldehyde
paranitrobenzaldehyde
p-nitro benzaldehyde
para-nitro benzaldehyde
p-nitro-benzaldehyde
4-nitrobenzaldhyde
STR00898
AC-27489
mfcd00007346
J-515873
CS-W007577
F2190-0630
4-nitrobenzaldehyde, purum, >=97.0% (hplc)
4-nitrobenzaldehyde, for spectrophotometric det. of amino sugars, >=99.0%
D70831
4-nitrobenzaldehyde, p.a., 98.0%
4-nitrobenzaldehyde, vetec(tm) reagent grade, 98%
SY001417
Q2816679
4-nitrobenzaldehyde,(s)
BCP27111
ccris-1675
nitrobenzaldehyde, 4-
4-nitrobenzenecarboxaldehyde
para nitro benzaldehyde
EN300-18420
4-nitrobenzaldehyde; chloramphenicol impurity b
Z57772464
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
benzaldehydesAny arenecarbaldehyde that consists of a formyl substituted benzene ring and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
4-nitrotoluene degradation I310

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency62.70690.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency19.44920.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency48.75650.000221.22318,912.5098AID1259243; AID1259381; AID743035; AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency60.92490.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.53520.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency45.63790.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency69.00830.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency38.27520.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency27.47270.001723.839378.1014AID743083
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.82490.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.82490.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
cellular aldehyde metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
lipid metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
xenobiotic metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
aldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
aldehyde dehydrogenase [NAD(P)+] activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
protein bindingAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
benzaldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
3-chloroallyl aldehyde dehydrogenase activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
extracellular spaceAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
endoplasmic reticulumAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
cytosolAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
plasma membraneAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
cytoplasmAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1766396Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by resazurin dye based fluorescence assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID1766407Electrochemical behavior of the compound in aprotic medium assessed as redox potential using glassy carbon electrode by cyclic voltammetry analysis2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1826431Substrate activity at N-terminal-His6 tagged recombinant human ALDH3A1 assessed as Kcat in presence of NADPH by fluorometric assay2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer.
AID1602658Inhibition of mouse GAT-1 assessed as percentage of remaining specific binding of NO711 at 1 uM after 4 hrs by LC-ESI-MS/ms analysis relative to control2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.
AID1766399Antileishmanial activity against Leishmania infantum MHOM/MA/67/ITMAP-263 promastigotes assessed as inhibition of parasite growth incubated for 72 hrs by resazurin dye based assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID1826429Substrate activity at N-terminal-His6 tagged recombinant human ALDH3A1 assessed as Km in presence of NADPH by fluorometric assay2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer.
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID1766397Antileishmanial activity against Leishmania amazonensis MHOM/BR/77/LTB 0016 promastigotes assessed as inhibition of parasite growth incubated for 72 hrs by resazurin dye based assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID1524436Substrate activity at recombinant Haemophilus influenzae Chloramphenicol nitroreductase expressed in Escherichia coli assessed as initial rate of reaction at 150 uM measured at 30 sec interval for 5 mins in presence of NADPH at pH 8 under 37 degC by UV-vi2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Investigating the promiscuity of the chloramphenicol nitroreductase from Haemophilus influenzae towards the reduction of 4-nitrobenzene derivatives.
AID1656235Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability2019European journal of medicinal chemistry, Feb-15, Volume: 164Green recipes to quinoline: A review.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID1573603Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM preincubated for 4 hrs followed by NO711 addition and measured after 40 mins by LC-ESI-MS/MS analysis relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID299876Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as edema weight at 20 mg/kg, po after 2 hrs relative to control2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes.
AID1766398Antileishmanial activity against intracellular Leishmania amazonensis MHOM/BR/77/LTB 0016 amastigotes infected in BALB/c mouse peritoneal macrophage assessed as reduced parasite growth incubated for 72 hrs by PANOTIC staining based assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (8.45)18.7374
1990's8 (11.27)18.2507
2000's17 (23.94)29.6817
2010's34 (47.89)24.3611
2020's6 (8.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.59 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index89.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]